Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differentiating the efficacy of 5-HT(1B/1D) agonists.

Headache - 1 Mar 2001

Sheftell F D, Fox A W, Weeks R E, Tepper S J

Abstract excerpt

OBJECTIVE: To examine, for a set of published clinical trials of serotonin (5-HT(1B/1D)) agonists as acute treatments for migraine, whether transformation of efficacy data into therapeutic gain (TG) or number needed to treat (NNT) is useful. BACKGROUND: Pivotal clinical trials of 5-HT(1B/1D) agonists in migraine use a primary end point of change in pain score from 3 or 2 to 1 or 0. Placebo response rates among...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Disease
Share to Genetic Variation
Share to Meta-Analysis as Topic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Migraine Disorders

Share to Placebos

Share to Research Design

Share to Sensitivity and Specificity

Share to Serotonin Receptor Agonists

Source

Identifiers

PMID: 11264685
DOI: 10.1046/j.1526-4610.2001.111006257.x

Genes

NNT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Differentiating the efficacy of 5-HT(1B/1D) agonists.PMID 11264685Read ↗

Reduction of pain and functional disability over time in patients treated with zavegepant: A Post-hoc analysis of the BHV3500-301 Phase 3 Randomized Controlled TrialSemantic proximity Read ↗

Recent advances in the management of migraineSemantic proximity Read ↗

Computational Design of Two New 5-HT <sub>1</sub> B Serotonin Receptor Agonists Derived from NaratriptanSemantic proximity Read ↗

Level of therapeutic innovation of new drugs for the treatment of migraineSemantic proximity Read ↗

What would 5-HT do? Regional diversity of 5-HT(1) receptor modulation of primary afferent neurotransmission.Semantic proximity Read ↗

The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysisSemantic proximity Read ↗

Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical PracticeSemantic proximity Read ↗

Migraine: disease characterisation, biomarkers, and precision medicineSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.